Evidence map›Paper›PMID 30653247›Full record

ReviewMovement disorders : official journal of the Movement Disorder Society2019

Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review.

Klaus Seppi, K Ray Chaudhuri, Miguel Coelho, Susan H Fox, Regina Katzenschlager, Santiago Perez Lloret, Daniel Weintraub, Cristina Sampaio, the collaborators of the Parkinson's Disease Update on Non-Motor Symptoms Study Group on behalf of the Movement Disorders Society Evidence-Based Medicine Committee

Erratum issued Registry-linked trialAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Movement disorders : official journal of the Movement Disorder Society, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT04851691 (A Pragmatic Randomized-controlled Trial of a Multi-pronged Electronic Health Record-based Clinical Decision Support Tool to Reduce Low-value Antipsychotic Prescriptions Among Older Adults With Alzheimer's and Related Dementias), which is not on this map. Cited by 460 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
460citing papers in PubMed, 10 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04851691 nacompletednot on this mapstarted 2021, after this paper: background citation

A Pragmatic Randomized-controlled Trial of a Multi-pronged Electronic Health Record-based Clinical Decision Support Tool to Reduce Low-value Antipsychotic Prescriptions Among Older Adults With Alzheimer's and Related Dementias

TypeinterventionalSponsorUniversity of California, Los AngelesRan2021 to 2023Enrolled158ConditionsAlzheimer Disease, Dementia Alzheimers, Dementia of Alzheimer TypeArmsEHR CDS, Usual Care
3 · Its place in the literature

Who cites it

460 citing papers in PubMed, 10 syntheses or guidelines pooled it.

  1. Pooled it
  2. Guideline
  3. Pooled it
  4. Management of Anxiety in Parkinson's Disease.Movement disorders clinical practice · 2025
    Pooled it
  5. Guideline
  6. Pooled it
  7. Pooled it
  8. Guideline
  9. Pooled it
  10. Pooled it
  11. Cognitive Orientation to Daily Occupational Performance (CO-OP) in Parkinson's: Randomized Trial Findings.Canadian journal of occupational therapy. Revue canadienne d'ergotherapie · 2026
    Trial
  12. Trial
  13. Trial
  14. A double-blind, controlled trial of circadian effective light therapy in patients with Parkinson's disease.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025
    Trial
  15. Trial
  16. Trial
  17. Trial
  18. Psilocybin therapy for mood dysfunction in Parkinson's disease: an open-label pilot trial.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2025
    Trial
  19. Trial
  20. Trial

400 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Klaus SeppiDepartment of Neurology, Medical University Innsbruck, Innsbruck, Austria.
K Ray ChaudhuriInstitute of Psychiatry, Psychology & Neuroscience at King's College and Parkinson Foundation International Centre of Excellence at King's College Hospital, Denmark Hill, London, United Kingdom.ORCID 0000-0003-2815-0505
Miguel CoelhoServiço de Neurologia, Hospital Santa Maria Instituto de Medicina Molecular Faculdade de Medicina de Lisboa, Lisboa, Portugal.
Susan H FoxEdmond J Safra Program in Parkinson Disease, Movement Disorder Clinic, Toronto Western Hospital, and the University of Toronto Department of Medicine, Toronto, Ontario, Canada.
Regina KatzenschlagerDepartment of Neurology and Karl Landsteiner Institute for Neuroimmunological and Neurodegenerative Disorders, Danube Hospital, Vienna, Austria.
Santiago Perez LloretInstitute of Cardiology Research, University of Buenos Aires, National Research Council, Buenos Aires, Argentina.ORCID 0000-0001-9069-6512
Daniel WeintraubDepartments of Psychiatry and Neurology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Cristina SampaioCHDI Management/CHDI Foundation, Princeton, NJ, USA.
the collaborators of the Parkinson's Disease Update on Non-Motor Symptoms Study Group on behalf of the Movement Disorders Society Evidence-Based Medicine Committee

Funding

International Parkinson and Movement Disorder Society
6 · The paper itself

Abstract

objectiveTo update evidence-based medicine recommendations for treating nonmotor symptoms in Parkinson's disease (PD).

backgroundThe International Parkinson and Movement Disorder Society Evidence-Based Medicine Committee's recommendations for treatments of PD were first published in 2002, updated in 2011, and now updated again through December 31, 2016.

methodsLevel I studies testing pharmacological, surgical, or nonpharmacological interventions for the treatment of nonmotor symptoms in PD were reviewed. Criteria for inclusion and quality scoring were as previously reported. The disorders covered were a range of neuropsychiatric symptoms, autonomic dysfunction, disorders of sleep and wakefulness, pain, fatigue, impaired olfaction, and ophthalmologic dysfunction. Clinical efficacy, implications for clinical practice, and safety conclusions are reported.

resultsA total of 37 new studies qualified for review. There were no randomized controlled trials that met inclusion criteria for the treatment of anxiety disorders, rapid eye movement sleep behavior disorder, excessive sweating, impaired olfaction, or ophthalmologic dysfunction. We identified clinically useful or possibly useful interventions for the treatment of depression, apathy, impulse control and related disorders, dementia, psychosis, insomnia, daytime sleepiness, drooling, orthostatic hypotension, gastrointestinal dysfunction, urinary dysfunction, erectile dysfunction, fatigue, and pain. There were no clinically useful interventions identified to treat non-dementia-level cognitive impairment.

conclusionsThe evidence base for treating a range of nonmotor symptoms in PD has grown substantially in recent years. However, treatment options overall remain limited given the high prevalence and adverse impact of these disorders, so the development and testing of new treatments for nonmotor symptoms in PD remains a top priority. © 2019 International Parkinson and Movement Disorder Society.

Indexed as

Evidence-Based MedicineTreatment OutcomeAnxiety DisordersCognition DisordersDepressionHumansParkinson Diseaseevidence-based medicinenon-motor symptomsParkinson's diseaserandomized controlled trial

Identifiers

PMID30653247
PMCPMC6916382

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.